Gedea Biotech

Gedea Biotech is a high-potential biotechnology company with a CE-marked product (pHyph) targeting bacterial vaginosis without antibiotics, directly addressing the global antimicrobial resistance crisis. External verification confirms significant traction, including a €2.5M EIC grant, successful Phase 2/3 clinical trials (NEFERTITI-2), and EU market approval as of late 2025. However, the project submission itself was of extremely low quality, containing false claims ('most people have used my product', 'everyone' audience) and data inconsistencies ('SwiftStorm' name). While the underlying technology and business utility are exceptional, the score is heavily penalized by the lack of credible evidence provided in the submission text.